ArticleBioFactors (Oxford, England)
Resveratrol-Derived Dimers With Antimicrobial and Immune-Enhancing Activities.
Article in BioFactors (Oxford, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In search for novel antibiotic candidates, polyphenols represent an unexploited source with a nearly inexhaustible number of promising compounds. In addition to the antimicrobial activity, some polyphenols modulate the immune response in a way that could enhance the clearance of invading pathogens. This study investigated four resveratrol-derived dimeric compounds, dehydro-δ-viniferin, (±)-trans-δ-viniferin, viniferifuran, and (±)-ε-viniferin, for their antimicrobial activity against methicillin-resistant S. aureus. In addition, their immunomodulating properties in bacterially challenged dendritic cells were assessed. We identified dehydro-δ-viniferin as exhibiting the most potent antimicrobial activity against methicillin-resistant Staphylococcus aureus with a minimal inhibitory concentration of 2 μg/mL and a minimal bactericidal concentration of 8 μg/mL, respectively. Furthermore, dehydro-δ-viniferin showed significant enhancement of the S. aureus-induced IL-12 production from bone marrow-derived dendritic cells, which could be ascribed to a decrease in the production of IL-10. Only if dehydro-δ-viniferin was administered to dendritic cells prior to bacterial stimulation, IL-12 production was increased; if added later, the increase in IL-12 was lost although the IL-10 production was reduced. This suggests that dehydro-δ-viniferin interferes with the signaling pathway leading to IL-10, which in turn influences the IL-12 production in a time dependent manner. Collectively, dehydro-δ-viniferin is a potent antimicrobial against methicillin-resistant S. aureus with enhancing effects on the bacterially induced IL-12 response in antigen-presenting cells. We therefore suggest dehydro-δ-viniferin as a promising antibiotic candidate against multidrug-resistant Gram-positive bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.